Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Operating Expenses (2018 - 2025)

10x Genomics (TXG) has disclosed Operating Expenses for 8 consecutive years, with $132.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 17.54% to $132.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $504.9 million through Dec 2025, down 17.1% year-over-year, with the annual reading at $504.9 million for FY2025, 17.1% down from the prior year.
  • Operating Expenses hit $132.6 million in Q4 2025 for 10x Genomics, roughly flat from $132.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $190.3 million in Q3 2023 to a low of $95.0 million in Q2 2025.
  • Historically, Operating Expenses has averaged $141.1 million across 5 years, with a median of $143.6 million in 2022.
  • Biggest YoY gain for Operating Expenses was 67.77% in 2021; the steepest drop was 73.8% in 2021.
  • Year by year, Operating Expenses stood at $131.8 million in 2021, then grew by 8.15% to $142.5 million in 2022, then rose by 19.98% to $171.0 million in 2023, then dropped by 5.95% to $160.8 million in 2024, then fell by 17.54% to $132.6 million in 2025.
  • Business Quant data shows Operating Expenses for TXG at $132.6 million in Q4 2025, $132.5 million in Q3 2025, and $95.0 million in Q2 2025.